GlassScriptPhysician profile
John F Riedler
NPI 1366414104
$728.83
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $35.08 · 2021: $26.76.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $268.24 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $154.49 | 2019 | |
| Sunovion Pharmaceuticals INC. | $90.34 | 2019 | |
| Allergan, INC. | $54.85 | 2019 | |
| Ironshore Pharmaceuticals INC. | $52.16 | 2019 | |
| Shire North American Group INC | $39.27 | 2019 | |
| Masimo Corporation | $26.76 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.82 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.10 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Riedler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.